Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting.

ABSTRACT:

Objective

To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy.

Design

Open-label, prospective, multi-center phase II trial.

Setting

Three institutions.

Participants

Fifty-four patients scheduled to receive CapeOX chemotherapy.

Interventions

Participants received GTDS (3.1 mg applied to the upper arm 48 h before chemotherapy, replaced on day 5, and discarded on day 12) and Dexamethasone.

Main outcome measures

The primary endpoint was the complete control rate of CINV. Secondary endpoints included the duration of delayed complete control, complete control

SUBMITTER: Wang C 

PROVIDER: S-EPMC11264757 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature